Albutec Inc
... was founded in 2022. Our mission: To advance ECAD to the next level through a proprietary platform technology for effective liver support that performs detoxification in an extracorporeal set-up with the utmost safety and usability. Our technology is protected by several granted and pending patents worldwide.
Leadership
David Derminio
President & CEO
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa.
Nick Skaff
Chief Financial Officer
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa.
Jan Stange, MD, PhD
Chief Medical Officer
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa.
Andrew Henry, BSc
Chief Clinical Operations
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa.
Jennifer Guzman
Director of Reimbursement and Marketing
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa.
Board:
Terrence Winters, Chairman
David Derminio, President and CEO
Jan Strange, MD, PhD, Chief Medical Officer
Michael Millis, MD, University of Chicago
After launching the CE marked Hepalbin®-Adsorbent-Technology for albumin dialysis in 2013 in Europe, a clinical trial was initiated to validate and compare performance data. Demonstrating superiority and significance in survival and recovery led to thousands of successful treatments in the EU. Motivated by these results exceeding the expectations the EU Team constantly enhanced the technology introducing the all-new modular Hepalbin MaxiCycler to the market in 2021. Based on that latest innovation Albutec Inc is preparing the market entrance in the US.